Single-Center Cohort of Pediatric Patients with High-Risk Neuroblastoma Receiving Immunotherapy
Our experiences confirm that immunotherapy, including Dinutuximab beta and Nivolumab, is safe and well tolerated. The standardization of the application of Dinutuximab beta and in combination with novel therapeutic agents in maintenance and refractory/relapsed cases may contribute to improved treatment outcome results.
Authors
- Sándor Barna (ORCID: https://orcid.org/0000-0002-0608-7704)
- Miklós Petrás
- Emese Zsigrai
- István Szegedi (ORCID: https://orcid.org/0000-0003-4181-4361)
- Csongor Kiss (ORCID: https://orcid.org/0000-0001-5170-5965)
- Zsuzsanna Gaál (ORCID: https://orcid.org/0009-0008-1097-3494)
- Lilla Macsi
Institutions
- University of Debrecen (HU)
Publication Details
- Journal
- Cancers
- Published
- 2025-05-30
- DOI
- https://doi.org/10.3390/cancers17111824
- Primary Topic
- Neuroblastoma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00